A phase 2 study of ianalumab (VAY736) in patients with primary immune thrombocytopenia (ITP) previously treated with at least two lines of therapies
Recruiting
99 years and younger
All
Phase
N/A
1 participants needed
1 Location
Brief description of study
- PURPOSE
- To evaluate the efficacy of ianalumab (i.e., platelet response 50 G/L) in participants with primary ITP previously treated with at least a corticosteroid and a TPO-RA. A platelet count of 50 G/L at two (or more) consecutive assessments at least 7 days apart between Week 1 Day 1 and Week 25 Day 1. Proportion of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 854766
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
